Omeros Corporation (NASDAQ:OMER) had its target price hoisted by stock analysts at S&P Equity Research from $7.65 to $8.63 in a research note issued on Monday. S&P Equity Research’s price objective suggests a potential upside of 14.00% from the company’s current price.
Several other research firms also recently commented on OMER. Zacks Investment Research downgraded shares of Omeros Corporation from a “hold” rating to a “sell” rating in a report on Wednesday, October 12th. Maxim Group reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Omeros Corporation in a report on Thursday, July 28th. FBR & Co reaffirmed an “outperform” rating and issued a $38.00 price objective on shares of Omeros Corporation in a report on Wednesday, June 29th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $21.00 price objective on shares of Omeros Corporation in a report on Wednesday, August 10th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $56.00 price objective (down from $62.00) on shares of Omeros Corporation in a report on Thursday, August 11th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $32.45.
Omeros Corporation (NASDAQ:OMER) traded up 3.54% during trading on Monday, reaching $7.60. The company had a trading volume of 3,868,671 shares. Omeros Corporation has a one year low of $7.26 and a one year high of $16.80. The company has a 50-day moving average price of $10.60 and a 200 day moving average price of $11.73. The company’s market capitalization is $298.63 million.
Omeros Corporation (NASDAQ:OMER) last released its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.32) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.50) by $0.18. The business earned $10 million during the quarter, compared to the consensus estimate of $9.80 million. The firm’s quarterly revenue was up 212.5% on a year-over-year basis. During the same period last year, the business posted ($0.44) earnings per share. Analysts expect that Omeros Corporation will post ($1.55) earnings per share for the current year.
In other Omeros Corporation news, VP Marcia S. Kelbon sold 16,000 shares of the stock in a transaction that occurred on Thursday, September 15th. The shares were sold at an average price of $10.91, for a total value of $174,560.00. Following the sale, the vice president now directly owns 179,597 shares in the company, valued at approximately $1,959,403.27. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Marcia S. Kelbon sold 15,900 shares of the stock in a transaction that occurred on Monday, August 15th. The stock was sold at an average price of $11.56, for a total transaction of $183,804.00. Following the completion of the sale, the vice president now owns 179,497 shares in the company, valued at $2,074,985.32. The disclosure for this sale can be found here. 13.60% of the stock is currently owned by company insiders.
Hedge funds have recently bought and sold shares of the company. Ingalls & Snyder LLC purchased a new stake in Omeros Corporation during the second quarter valued at about $46,441,000. Bank of Montreal Can purchased a new stake in Omeros Corporation during the second quarter valued at about $17,641,000. BlackRock Fund Advisors boosted its stake in Omeros Corporation by 0.7% in the first quarter. BlackRock Fund Advisors now owns 1,471,968 shares of the biopharmaceutical company’s stock valued at $22,580,000 after buying an additional 10,605 shares in the last quarter. Vanguard Group Inc. boosted its stake in Omeros Corporation by 2.3% in the second quarter. Vanguard Group Inc. now owns 1,430,125 shares of the biopharmaceutical company’s stock valued at $15,045,000 after buying an additional 32,401 shares in the last quarter. Finally, State Street Corp boosted its stake in Omeros Corporation by 16.8% in the second quarter. State Street Corp now owns 881,993 shares of the biopharmaceutical company’s stock valued at $9,274,000 after buying an additional 126,595 shares in the last quarter. Institutional investors and hedge funds own 48.04% of the company’s stock.
About Omeros Corporation
Omeros Corporation is a biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company’s marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens replacement.
Receive News & Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related companies with MarketBeat.com's FREE daily email newsletter.